Design and development of oxyclozanide chewable tablet formulation employing quality by design approach

dc.contributor.authorÖzalp, Yıldız
dc.contributor.authorAboubakr, Adel
dc.contributor.authorOnayo, Motunrayo Mayowa
dc.contributor.authorKebede, Hassen
dc.contributor.authorJiwa, Nailla
dc.contributor.authorAksu, Neşe Buket
dc.date.accessioned2023-07-21T08:37:22Z
dc.date.available2023-07-21T08:37:22Z
dc.date.issued2023en_US
dc.departmentFakülteler, Eczacılık Teknolojisi Bilimleri Bölümü, Farmasötik Teknoloji Ana Bilim Dalıen_US
dc.description.abstractBackground: The focus of this research was to identify undiscovered knowledge associated with the production of oxyclozanide tablets utilizing Quality by Design (QbD) in order to develop an ideal formulation that would guarantee constant product quality. The modern approach to formulation design and optimization essentially entails QbD which is a systemic method of pharmaceutical development and comprises of the design and development of formulations as well as manufacturing processes to meet the target product quality. Materials and Methods: Pre-formulation studies on excipient flow properties, compactibility and tabletability profiles, identification of Critical Process Parameters (CPP) and Critical Quality Attributes (CQA) were carried out. An experimental design was adopted to investigate the effect of formulation and process variables (compression force, super-disintegrant type and concentration) on the CQAs using Modde Pro 12.1. The obtained results were used to generate a Design Space (DS) based on the study data. Results: Preformulation studies carried out on the core excipients used, gave an understanding to their tabletability and compactibility. Process parameters such a compaction force and formulation variables such as super-disintegrant concentration were studied within the framework of Quality by Design (QbD) and the new optimized formulation derived was tested and confirmed to be within the design space generated. Conclusion: At the end of the study, the aim was achieved; which was to implement pre-formulation studies and QbD to design a formulation containing Oxyclozanide (API) with a combination of excipients.en_US
dc.identifier.citationOzalp, Y., Aboubakr, A., Onayo, M. M., Kebede, H., Jiwa, N., & Aksu, N. B. (2023). Design and development of oxyclozanide chewable tablet formulation employing quality by design approach. Indian Journal of Pharmaceutical Education and Research, 57(2), s434-s441.en_US
dc.identifier.endpages441en_US
dc.identifier.issn0019-5464
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85163755011
dc.identifier.scopusqualityQ3
dc.identifier.startpages434en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12939/3575
dc.identifier.volume57en_US
dc.identifier.wosWOS:001009346300030
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.institutionauthorAksu, Neşe Buket
dc.language.isoen
dc.publisherAssociation of Pharmaceutical Teachers of Indiaen_US
dc.relation.ispartofIndian Journal of Pharmaceutical Education and Research
dc.relation.isversionof10.5530/ijper.57.2s.51en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChewable tableten_US
dc.subjectCompactibilityen_US
dc.subjectOxyclozanideen_US
dc.subjectQuality by Design (QbD)en_US
dc.subjectTabletabilityen_US
dc.titleDesign and development of oxyclozanide chewable tablet formulation employing quality by design approach
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
IndJPhaEdRes-57-2s-434 (1).pdf
Boyut:
496.44 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: